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Introduction
Farber lipogranulomatosis (Farber Disease; FD) is an
ultra-rare lysosomal storage disorder resulting from the
inherited deficiency of the enzyme acid ceramidase, and
the accumulation of the lipid substrate, ceramide.
Ceramide is a pro-inflammatory and pro-apoptotic lipid
that has been implicated in the pathogenesis of cartilage
disorders. Farber Disease has a heterogeneous presentation
ranging from a severe phenotype with respiratory and
CNS involvement with an average life expectancy of
1.3 years, to a moderate phenotype, which generally
includes joint swelling, contractures and pain. The clinical
similarity between the moderate Farber phenotype and the
more severe forms of Juvenile Idiopathic Arthritis (JIA)
suggests that moderate Farber Disease cases may be
diagnosed as JIA in some cases.
Objectives
To demonstrate the presentation, phenotype and patho-
physiology of Farber Disease, and to show that moderate
Farber Disease should be considered in certain cases of
early-onset polyarticular arthritis in children. In addition,
we address how the diagnosis of Farber Disease is
established and the potential effectiveness of enzyme
replacement therapy.
Methods
We present a case study to demonstrate the moderate
Farber phenotype and the results of a literature search
of Farber Disease case studies since 1990. The back-
ground for enzyme replacement therapy (enzyme uptake
and decrease of ceramide levels in vitro) also is outlined.
Results
The patient described was originally diagnosed with JIA.
The clinical suspicion of Farber Disease was raised by a
pediatric rheumatologist with experience in lysosomal
storage diseases. His leukocyte acid ceramidase activity
is ~4% of his parents, and his ceramide levels are ~2
times that of his parents. Genetic testing revealed a
homozygous mutation in the ASAH1 gene. He is cur-
rently 9 years old and receiving anti-inflammatory ther-
apy including a TNF-alpha blocker. He has no CNS
involvement, but his joint disease continues to progress.
Of the published Farber Disease case studies since 1990,
40% (n=14) described patients with moderate disease.
36% (n=5) of these patients were initially diagnosed as
having JIA. To establish proof-of-concept for enzyme
replacement therapy of Farber Disease, recombinant
human acid ceramidase was produced in Chinese ham-
ster ovary cells and added to the culture media of
human Farber cells, resulting in a significant reduction
in ceramide levels.
Conclusion
A high percentage of moderate Farber Disease patients are
likely initially suspected of having JIA. Given this finding,
it is important to increase awareness of Farber Disease in
the pediatric rheumatology community. Differential diag-
nosis can be made by accounting for the comparatively
early onset, progressive symmetric arthritis, presence of
subcutaneous nodules in the joints, scalp and/or spine,
and an unusual, hoarse cry or voice (due to nodule forma-
tion on the larynx) in Farber Disease patients. Based on
experience with Farber Disease cells and with bone
marrow transplantation in Farber Disease patients, enzyme
replacement therapy could reduce ceramide levels and
resolve or significantly attenuate the arthritis phenotype in
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patients. Such therapy is currently under development. We
propose that Farber Disease can account for specific cases
diagnosed as JIA, and that clinically guided screening of
the JIA population will reveal patients who will benefit
from disease-specific care and treatment.
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